Caitlin Costello, MD

A discussion on choosing between triplet or quadruplet induction therapy for transplant-eligible newly diagnosed multiple myeloma.

An overview of the triplet and quadruplet induction treatment regimens available for patients with transplant-eligible multiple myeloma and key clinical trials studying daratumumab and isatuximab presented at ASH 2021, with emphasis on the GRIFFIN, MASTER and GMMG-HD7 studies.

A panel of hematologists/oncologists conclude a discussion about transplant-ineligible multiple myeloma (MM) by reacting to current treatment gaps that need to be addressed.

Recommendations when talking with patients with transplant-ineligible multiple myeloma (MM) who request to stop receiving treatment.

Triggers that may lead a hematologist/oncologist to consider reinstituting therapy for a patient with transplant-ineligible multiple myeloma (MM) who received prior therapy but was not treated to progression.

The rationale behind treating patients with newly diagnosed transplant-ineligible multiple myeloma (MM) until disease progression rather than stopping therapy at a designated point in time.

Take-home points from the MAIA trial of daratumumab plus lenalidomide and dexamethasone as therapy for patients with newly diagnosed transplant-ineligible multiple myeloma, and recommendations regarding maintenance therapy following the use of a triplet regimen.

Scenarios for which a doublet regimen may be recommended over a triplet therapy for the management of newly diagnosed transplant-ineligible multiple myeloma.

A panel of hematologist-oncologists comment on how they would treat a 74-year-old patient with newly diagnosed transplant-ineligible multiple myeloma.

Recommended next steps regarding treatment for patients with transplant-ineligible multiple myeloma based on prior responses to therapy.

Current techniques used to assess MRD status in patients with multiple myeloma, and advice to hematologist-oncologists who are considering flow cytometry or molecular testing.

Recommendations for measuring treatment response in patients with multiple myeloma utilizing tests such as MRD assessments.

Different markers and tests that are used to monitor disease status and treatment response in patients with multiple myeloma.

Kicking off a discussion regarding treatment approaches for transplant-ineligible multiple myeloma, a panel of hematologist-oncologists highlights goals of therapy for newly diagnosed patients.

A 60-year-old man with a history of coronary artery disease and JAK2 V617F–positive polycythemia vera presented to our bone marrow transplantation clinic with progressive fatigue, splenomegaly, and cytopenias.